The U.S. Food and Drug Administration (FDA) has approved octagam 10% [Immune Globulin Intravenous (Human)] for the treatment of dermatomyositis (DM) in adults1, a rare, immune-mediated inflammatory disease.
FDA approval for the new indication was based on the results of ProDERM, a pivotal randomized clinical trial and the first to evaluate the long-term efficacy and safety of IVIg therapy for adults with DM.
If you'd like to talk to an Octapharma Medical Science Liaison about octagam 10% and stay current on product updates, just complete and submit the form.